Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26522984  

The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia.

Nancy Pinnell | Ran Yan | Hyo Je Cho | Theresa Keeley | Marcelo J Murai | Yiran Liu | Amparo Serna Alarcon | Jason Qin | Qing Wang | Rork Kuick | Kojo S J Elenitoba-Johnson | Ivan Maillard | Linda C Samuelson | Tomasz Cierpicki | Mark Y Chiang
Immunity | 2015

Pan-NOTCH inhibitors are poorly tolerated in clinical trials because NOTCH signals are crucial for intestinal homeostasis. These inhibitors might also promote cancer because NOTCH can act as a tumor suppressor. We previously reported that the PIAS-like coactivator ZMIZ1 is frequently co-expressed with activated NOTCH1 in T cell acute lymphoblastic leukemia (T-ALL). Here, we show that similar to Notch1, Zmiz1 was important for T cell development and controlled the expression of certain Notch target genes, such as Myc. However, unlike Notch, Zmiz1 had no major role in intestinal homeostasis or myeloid suppression. Deletion of Zmiz1 impaired the initiation and maintenance of Notch-induced T-ALL. Zmiz1 directly interacted with Notch1 via a tetratricopeptide repeat domain at a special class of Notch-regulatory sites. In contrast to the Notch cofactor Maml, which is nonselective, Zmiz1 was selective. Thus, targeting the NOTCH1-ZMIZ1 interaction might combat leukemic growth while avoiding the intolerable toxicities of NOTCH inhibitors.

Pubmed ID: 26522984

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01-CA196604
  • Agency: NCI NIH HHS, United States
    Id: P30-CA46592
  • Agency: NCI NIH HHS, United States
    Id: P30 CA046592
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI091627
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK096972
  • Agency: NCI NIH HHS, United States
    Id: T32 CA009676
  • Agency: NIDDK NIH HHS, United States
    Id: R01-DK078927
  • Agency: NCI NIH HHS, United States
    Id: R01 CA196604
  • Agency: NIAID NIH HHS, United States
    Id: R01-AI091627
  • Agency: NCI NIH HHS, United States
    Id: T32-CA009676-22
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK078927

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Cell Signaling Technology (tool)

RRID:SCR_004431

Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

View all literature mentions

International Mouse Phenotyping Consortium (IMPC) (tool)

RRID:SCR_006158

Center that produces knockout mice and carries out high-throughput phenotyping of each line in order to determine function of every gene in mouse genome. These mice will be preserved in repositories and made available to scientific community representing valuable resource for basic scientific research as well as generating new models for human diseases.

View all literature mentions